Pharmac

Please see below updates from Pharmac. Supply issue Pimafucort Ointment Pioglitazone tab 15 mg and tab 30 mg (Vexazone) Vannair Metered dose inhalers (budesonide/eformoterol) Brand change Coversyl tabs salt change Discontinuation Epilim tab 100 mg crushable date extended 1.Supply issue: Pimafucort Ointment There is an upcoming long-term supply issue affecting Pimafucort ointment. The supplier has advised that due to a significant manufacturing issue affecting an i

Pharmac has made changes to improve access to funded HIV medicines, making it easier for people living with HIV, or at risk of acquiring HIV, to access treatment when they need them. From 1 November 2026, people will no longer need to meet Special Authority or Hospital Restriction criteria to access funded antiretroviral medicines. We've also made two antiretroviral medicines, emtricitabine with tenofovir disoproxil and dolutegravir, available on a Practitioner's Supply Order

Pharmac has made changes to improve access to funded HIV medicines, making it easier for people living with HIV, or at risk of acquiring HIV, to access treatment when they need them. From 1 November 2026, people will no longer need to meet Special Authority or Hospital Restriction criteria to access funded antiretroviral medicines. We've also made two antiretroviral medicines, emtricitabine with tenofovir disoproxil and dolutegravir, available on a Practitioner's Supply Order

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 16 October 2026. It includes information on: New updates Discontinuations New updates Discontinuation date change: Epilim Crushable 100 mg tablets Pharmac would like to inform you that we have secured additional supply of Epilim Crushable 100 mg tablets through to December next year (2027). We are working to identify alternative options for pe

Pimafucort ointment (Hydrocortisone with natamycin and neomycin) LEO, the supplier, will be out of stock of Pimafucort ointment (Pharmacode: 260282) for more than 12 months from November 2026. People will need a prescription for a different treatment. Pimafucort ointment (Hydrocortisone with natamycin and neomycin) Updated supply notices Mercaptopurine (Puri-Nethol) 50 mg tablet A shipment of this product (Pharmacode: 261270) has arrived and the supplier has released stock to

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 23 October 2026. It includes information on: New updates Discontinuations Reminders Resolved Supply Issues New updates Supply issue: Pimafucort Ointment There is an upcoming long-term supply issue affecting Pimafucort ointment. The supplier has advised that due to a significant manufacturing issue affecting an ingredient used in the product, stoc

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 9 October 2026. It includes information on: New updates Discontinuations Reminders New updates Supply issue: Sildenafil (Vedafil) 50mg tablets There is a supply issue affecting sildenafil (Vedafil) 50mg tablets. Pharmac previously funded a Section 29 alternate brand, Sildenafil (Amarox), in August this year. Stock of this brand is now very low and

Pharmac has decided to fund a new medicine for people in hospital with serious infections and to improve access to medicines for difficult-to-treat bacterial infections and high blood pressure.From 1 November 2026, Pharmac will: Fund ceftolozane with tazobactam for people with serious multidrug-resistant bacterial infections. Widen access to bedaquiline and linezolid for people with non-tuberculous mycobacterial infections. Widen access to captopril oral liquid for people wit

Flamazine cream discontinuation The supplier, Smith & Nephew, will stop supplying Flamazine cream (Pharmacode: 2343851) sulfadiazine silver 1% to the New Zealand market. Stock is expected to run out in December 2026/January 2027. Flamazine cream discontinuation Glibenclamide (Daonil) tab 5 mg discontinuation The supplier, Sanofi, is discontinuing Daonil (glibenclamide) tab 5 mg globally. Stock is expected to run out in February 2027. Glibenclamide (Daonil) tab 5 mg disconti

Please see below updates from Pharmac. Supply issue Medsafe approval, Teriparatide Teva Inj 250 mcg per ml, 2.4 ml Brand change Cetirizine hydrochloride oral liquid 1mg/ml 1.Supply Issue update: Medsafe approval, Teriparatide Teva Inj 250 mcg per ml, 2.4 ml An alternate product was funded from August - Teriparatide S29 20 micrograms/80 microlitres, solution for Injection Pre-filled Pen 2.4 ml This UK-branded teriparatide has now received approval from Medsafe. It can

Please see below updates from Pharmac. Supply issue Sildenafil (Vedafil) 50mg tablets. Hydrocortisone acetate (Colifoam) rectal foam 10% Venlafaxine 75 mg capsules (Enlafax XR) Brand change Dimethicone cream 10% pump bottle Discontinuation Daonil (glibenclamide) tab 5 mg Flamazine (silver sulfadiazine cream 1%) 1.Supply Issue: Sildenafil (Vedafil) 50mg tablets There is a supply issue affecting sildenafil (Vedafil) 50mg tablets. Pharmac previously funded a Section 29 a

New supply notices Colifoam (hydrocortisone acetate rectal foam) Colifoam (Pharmacode: 2611120) may go out of stock during October 2026. Two alternative products are funded from 8 October. Details are on the website. Colifoam (hydrocortisone acetate rectal foam) Venlafaxine (Enlafax XR) 75 mg capsule The supplier expects to run out this product (Pharmacode: 2713411) by mid-October. We have funded an alternative from 8 October. Details are on the website. Venlafaxine (Enlafax

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 2 October 2026. It includes information on: Reminders Resolved Supply Issues Discontinuation Reminder: Sodium valproate (Epilim) 100mg crushable tablets Sanofi expects that stock will be available until the end of November 2026. Please transition affected patients as soon as possible. For more information Epilim discontinuation on Pharmac website C

Contents Expanding Extended Pharmacy Services New supply notices Updated supply notices Consultations and notifications Monthly updates Decision to expand Extended Pharmacy Services (EPS) From 1 October 2026 the range of funded medicines community pharmacies can provide directly to people in their communities will be expanded further to include: Treatments for children with mild dermatitis Treatments for children with bacterial and fungal skin infections Treatments for childr

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 25 September 2026. It includes information on: New updates Reminders Resolved Supply Issues New updates New listing: Rubifen LA for ADHD and narcolepsy From 1 October 2026, Rubifen LA capsules will be funded for people with ADHD and narcolepsy who meet existing eligibility criteria. This is a generic version of Ritalin LA, in the same strengths (10

Health New Zealand and Pharmac have made the decision to extend pharmacy services. This decision means community pharmacies will be able to provide a wider range of funded clinical services for additional common conditions that may have otherwise required a GP visit, including: Treatments for children with skin infections Treatments for children with oral thrush Treatments for vaginal thrush Oral contraceptives Mild Dermatitis Changes will be made to the Pharmaceutical Sched

Please see below updates from Pharmac. Supply issue Fluconazole 150 mg capsule Sumatriptan 50 mg and 100mg tablets Sildenafil 25 mg tablets Ezetimibe with simvastatin (Zimybe) combination tablets (all strengths) Risperidone 1mg tablets Brand change Entecavir 0.5 mg tablets Discontinuation Reminder of insulin discontinuations. Prazosin discontinuation and new brand, all strengths Digoxin oral liq 50 mcg per ml 1.Supply Issue: Fluconazole 150 mg capsules There is a supp

New supply notices Brand change: Cyclopentolate and tropicamide eye drops These eye drops are changing brand to Minims (funded from 1 Oct 26). The new brand comes in single-use vials. Details of the new brand are on the website. Cyclopentolate and tropicamide eye drops Brand change: Dapsone (25 mg and 100 mg) The Dapsone brand is changing to Dapsomed (funded from 1 Oct 26). Details about the differences between the two brands are available on the website. A brand switch fee w

From 1 February 2027, Pharmac will fund additional strengths of levothyroxine tablets to support more flexible and accurate dosing for people with hypothyroidism. The change follows clinical advice that people taking levothyroxine may require precise dose adjustments, and that currently funded strengths may not always support the most convenient dosing regimen. The new strength options may reduce the need for alternate-day dosing regimens, and the need to combine multiple tab

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 11 September 2026. It includes information on: New updates Reminders Resolved Supply Issues New updates Widening of Access: rosuvastatin removal of Special Authority From 1 October 2026, rosuvastatin will no longer require a Special Authority for funded access. This means it is open listed and may be prescribed funded to any New Zealander when cli